Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
BMJ Medicine
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada
Retrieved June 11, 2025, from Grant, R., Berg, J., Mestayer, R., et al
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
Your mouth should be free of food, gum, candy, and anything flavored
US$ 21.52
US$ 21.57
US$ 28.85
US$ 21.87
US$ 21.44
US$ 25.69
